{"id":17417,"date":"2024-12-10T16:35:24","date_gmt":"2024-12-10T08:35:24","guid":{"rendered":"https:\/\/flcube.com\/?p=17417"},"modified":"2024-12-10T16:35:28","modified_gmt":"2024-12-10T08:35:28","slug":"jiangsu-hengrui-pharmaceuticals-plans-secondary-listing-on-hong-kong-stock-exchange","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17417","title":{"rendered":"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange"},"content":{"rendered":"\n

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276<\/a>) has confirmed reports regarding its intention to make a secondary listing on the Hong Kong Stock Exchange. According to a statement released on the Shanghai Stock Exchange, the Chinese pharmaceutical company is poised to engage Ernst & Young as its auditor, following approval from its board of directors.<\/p>\n\n\n\n

Engagement of Auditor and Implications of the Listing<\/strong>
The decision to hire Ernst & Young as the auditor for the secondary listing indicates a significant step forward in the company’s capital market strategy. The move is reportedly valued at a USD 2 billion windfall, although no specific unit price has been disclosed at this stage. This development underscores Hengrui Pharmaceuticals’ commitment to expanding its investor base and enhancing its global market presence.<\/p>\n\n\n\n

Strategic Significance of the Secondary Listing<\/strong>
The secondary listing on the Hong Kong Stock Exchange is expected to provide Jiangsu Hengrui Pharmaceuticals with increased access to international capital, diversifying its investor base and potentially boosting its liquidity. The listing will also facilitate greater exposure to global investors, highlighting the company’s growth prospects and solidifying its position within the pharmaceutical industry.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make…<\/p>\n","protected":false},"author":1,"featured_media":17418,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2586,72,852],"class_list":["post-17417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hengrui-pharmaceuticals","tag-ipo","tag-sha-600276"],"yoast_head":"\nJiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make a secondary listing on the Hong Kong Stock Exchange. According to a statement released on the Shanghai Stock Exchange, the Chinese pharmaceutical company is poised to engage Ernst & Young as its auditor, following approval from its board of directors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17417\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17417\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-10T08:35:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T08:35:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1073.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange\",\"datePublished\":\"2024-12-10T08:35:24+00:00\",\"dateModified\":\"2024-12-10T08:35:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417\"},\"wordCount\":202,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1073.png\",\"keywords\":[\"Hengrui Pharmaceuticals\",\"IPO\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17417#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17417\",\"name\":\"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1073.png\",\"datePublished\":\"2024-12-10T08:35:24+00:00\",\"dateModified\":\"2024-12-10T08:35:28+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make a secondary listing on the Hong Kong Stock Exchange. According to a statement released on the Shanghai Stock Exchange, the Chinese pharmaceutical company is poised to engage Ernst & Young as its auditor, following approval from its board of directors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17417\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1073.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1073.png\",\"width\":1080,\"height\":628,\"caption\":\"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17417#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make a secondary listing on the Hong Kong Stock Exchange. According to a statement released on the Shanghai Stock Exchange, the Chinese pharmaceutical company is poised to engage Ernst & Young as its auditor, following approval from its board of directors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17417","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=17417","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-10T08:35:24+00:00","article_modified_time":"2024-12-10T08:35:28+00:00","og_image":[{"width":1080,"height":628,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1073.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17417#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17417"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange","datePublished":"2024-12-10T08:35:24+00:00","dateModified":"2024-12-10T08:35:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17417"},"wordCount":202,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=17417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1073.png","keywords":["Hengrui Pharmaceuticals","IPO","SHA: 600276"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17417#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17417","url":"https:\/\/flcube.com\/?p=17417","name":"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=17417#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=17417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1073.png","datePublished":"2024-12-10T08:35:24+00:00","dateModified":"2024-12-10T08:35:28+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make a secondary listing on the Hong Kong Stock Exchange. According to a statement released on the Shanghai Stock Exchange, the Chinese pharmaceutical company is poised to engage Ernst & Young as its auditor, following approval from its board of directors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17417#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17417"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=17417#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1073.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1073.png","width":1080,"height":628,"caption":"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17417#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1073.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17417"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17417\/revisions"}],"predecessor-version":[{"id":17419,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17417\/revisions\/17419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/17418"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}